We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current XRTX market cap is 2.62M. The company's latest EPS is USD -1.0801 and P/E is -1.21.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -368k | -1.14M | -2.91M | -10.29M | -6.05M |
| Net Income | -629k | -1.28M | -1.58M | -7.72M | -2.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.09M | 2.29M | 17.38M | 12.37M | 5.47M |
| Total Liabilities | 1.3M | 1.03M | 4.18M | 5.38M | 826k |
| Total Equity | -211k | 1.26M | 13.2M | 7M | 4.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -249k | -728k | -4.8M | -8.96M | -6.58M |
| Investing | -7k | -14k | -32k | -46k | -46k |
| Financing | 55k | 855k | 19.37M | 4.71M | -361k |
| Market Cap | 2.62M |
| Price to Earnings Ratio | -1.21 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.76 |
| Price to Book Ratio | 0.56 |
| Dividend Yield | - |
| Shares Outstanding | 2M |
| Average Volume (1 week) | 8.2k |
| Average Volume (1 Month) | 7.07k |
| 52 Week Change | -60.78% |
| 52 Week High | 9.35 |
| 52 Week Low | 1.26 |
| Spread (Intraday) | 0.02 (1.5%) |
| Company Name | Xortx Therapeutics Inc |
| Address |
550 burrard street, suite 2900 vancouver, british columbia V6C OA3 |
| Website | https://www.xortx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
